{"id":"https://openalex.org/W2081550080","doi":"https://doi.org/10.2174/1568015024606646","title":"Glutamate and Schizophrenia: Pathophysiology and Therapeutics","display_name":"Glutamate and Schizophrenia: Pathophysiology and Therapeutics","publication_year":2002,"publication_date":"2002-03-01","ids":{"openalex":"https://openalex.org/W2081550080","doi":"https://doi.org/10.2174/1568015024606646","mag":"2081550080"},"language":"en","primary_location":{"id":"doi:10.2174/1568015024606646","doi":"https://doi.org/10.2174/1568015024606646","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1568015024606646","pdf_url":null,"source":{"id":"https://openalex.org/S2765063124","display_name":"Central Nervous System Agents in Medicinal Chemistry","issn_l":"1568-0150","issn":["1568-0150","1871-5249","1875-6158","1875-6166"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","medline","norway-1","poland-40","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medicinal Chemistry-Central Nervous System Agents","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004332028","display_name":"Gerard J. Marek","orcid":"https://orcid.org/0000-0001-8103-4306","observed_orcids":["https://orcid.org/0000-0001-8103-4306"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"G. Marek","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5004332028"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1825,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.56663177,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"1","first_page":"29","last_page":"44"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9839000105857849,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9839000105857849,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.008899999782443047,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glutamate","display_name":"glutamate","score":0.7879999876022339},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/glutamatergic-system","display_name":"glutamatergic system","score":0.7929999828338623},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9380000233650208},{"id":"https://openalex.org/keywords/5-ht2a-receptor","display_name":"5-HT2A receptor","score":0.8610000014305115},{"id":"https://openalex.org/keywords/dopamine","display_name":"dopamine","score":0.527999997138977},{"id":"https://openalex.org/keywords/thalamocortical-circuits","display_name":"thalamocortical circuits","score":0.949999988079071},{"id":"https://openalex.org/keywords/nmda-receptor","display_name":"NMDA receptor","score":0.9020000100135803},{"id":"https://openalex.org/keywords/ampa-receptors","display_name":"AMPA receptors","score":0.996999979019165},{"id":"https://openalex.org/keywords/metabotropic-glutamate-receptors","display_name":"metabotropic glutamate receptors","score":0.9559999704360962},{"id":"https://openalex.org/keywords/hallucinogens","display_name":"hallucinogens","score":0.7620000243186951},{"id":"https://openalex.org/keywords/psychotomimetic-drugs","display_name":"psychotomimetic drugs","score":0.8240000009536743},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.6430000066757202},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.6970000267028809},{"id":"https://openalex.org/keywords/neurotoxicity","display_name":"neurotoxicity","score":0.7020000219345093}],"concepts":[{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.7395559549331665},{"id":"https://openalex.org/C10162356","wikidata":"https://www.wikidata.org/wiki/Q1135939","display_name":"Pathophysiology","level":2,"score":0.6909734010696411},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.508243978023529},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4151194989681244},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34095776081085205},{"id":"https://openalex.org/C188147891","wikidata":"https://www.wikidata.org/wiki/Q147638","display_name":"Cognitive science","level":1,"score":0.33217859268188477},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3027074337005615},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12066447734832764}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2174/1568015024606646","doi":"https://doi.org/10.2174/1568015024606646","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1568015024606646","pdf_url":null,"source":{"id":"https://openalex.org/S2765063124","display_name":"Central Nervous System Agents in Medicinal Chemistry","issn_l":"1568-0150","issn":["1568-0150","1871-5249","1875-6158","1875-6166"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","medline","norway-1","poland-40","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medicinal Chemistry-Central Nervous System Agents","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9476000070571899}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2074169473","https://openalex.org/W2139906848","https://openalex.org/W2093696735","https://openalex.org/W2025740085","https://openalex.org/W2125215108","https://openalex.org/W2394619433","https://openalex.org/W2318734565","https://openalex.org/W2002705606","https://openalex.org/W2156035025","https://openalex.org/W2170774013"],"abstract_inverted_index":{"Since":[0],"the":[1,3,14,27,45,117,122,125,136,141,155,165,175,183,187,201,204,241],"1950s,":[2],"major":[4],"thrust":[5],"of":[6,68,110,144,167,200,206,213],"antipsychotic":[7,19,47,59,84,93,169],"drugs":[8,20,48,85,94,145,170],"development":[9],"has":[10,33],"been":[11,34],"centered":[12],"around":[13],"monoamine":[15],"dopamine":[16,23],"since":[17],"all":[18],"potently":[21,53],"block":[22,54],"receptors.":[24,248],"However,":[25,89],"in":[26,42,61,190],"last":[28],"fifteen":[29],"years":[30],"increasing":[31],"attention":[32],"focused":[35],"on":[36,174,233],"serotonin":[37],"(5-HT),":[38],"and":[39,78,108,121,157,216],"5-HT2A":[40],"receptors":[41,218,236],"particular":[43,74],"as":[44,116],"atypical":[46,58,92],"(e.g.,":[49],"clozapine,":[50],"olanzepine,":[51],"risperidone)":[52],"this":[55],"receptor.":[56],"These":[57],"drugs,":[60],"addition":[62],"to":[63,131,221,240],"having":[64],"a":[65,193,196],"decreased":[66],"incidence":[67],"motor":[69],"side":[70],"effects,":[71],"also":[72],"improve":[73],"symptoms":[75,77],"(negative":[76],"cognitive":[79],"dysfunction)":[80],"upon":[81,152],"which":[82,146],"typical":[83],"exert":[86],"little":[87],"effect.":[88],"even":[90],"these":[91,111,234],"have":[95,104],"limited":[96],"efficacy":[97],"for":[98],"many":[99],"patients.":[100],"Current":[101],"neuroimaging":[102],"studies":[103],"implicated":[105],"cortical-striatal-thalamic":[106],"circuits":[107,112],"interactions":[109,153],"with":[113],"areas":[114],"such":[115],"hippocampus,":[118],"pontine":[119],"nuclei":[120],"cerebellum.":[123],"Within":[124],"thalamocortical":[126],"pathways,":[127],"clear":[128],"abnormalities":[129],"appear":[130],"be":[132,150],"pres":[133],"ent":[134],"within":[135],"glutamate":[137,176,246],"system.":[138,177],"In":[139],"addition,":[140],"psychotomimetic":[142],"effects":[143],"induce":[147],"psychosis":[148],"may":[149],"dependent":[151],"between":[154],"monoamines":[156],"glutamate.":[158],"Therefore,":[159],"current":[160],"strategies":[161],"are":[162],"directed":[163],"toward":[164],"discovery":[166],"novel":[168],"that":[171,211],"act":[172],"directly":[173],"The":[178],"largest":[179],"unresolved":[180],"answer":[181],"facing":[182,203],"field":[184],"is":[185,192,210],"whether":[186],"critical":[188],"problem":[189],"schizophrenia":[191],"\u201dhypoglutamatergic\u201c":[194],"or":[195,237],"\u201dhyperglutamatergic\u201c":[197],"state.":[198],"One":[199],"dangers":[202],"strategy":[205],"enhancing":[207],"glutamatergic":[208],"transmission":[209],"overactivation":[212],"ionotropic":[214,235],"NMDA":[215],"AMPA":[217],"can":[219],"lead":[220],"neurotoxicity.":[222],"Thus":[223],"directions":[224],"being":[225],"pursued":[226],"involve":[227],"more":[228],"subtly":[229],"modulating":[230],"regulatory":[231],"sites":[232],"directing":[238],"agents":[239],"modulatory":[242],"G-protein":[243],"coupled":[244],"metabotropic":[245],"(mGlu)":[247],"Keywords:":[249],"Glutamate,":[250],"Schizophrenia,":[251],"Hallucinogenic":[252],"Drugs":[253]},"counts_by_year":[],"updated_date":"2026-07-31T08:31:51.225901","created_date":"2016-06-24T00:00:00"}